Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report

Lung Cancer

Volumn 109, Issue , 2017, Pages 42-44

  Uenami, Takeshi ^a   Hosono, Yuki ^a   Ishijima, Mikako ^a   Kanazu, Masaki ^a   Akazawa, Yuki ^a   Yano, Yukihiro ^a   Mori, Masahide ^a   Yamaguchi, Toshihiko ^a   Yokota, Soichiro ^a  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Lung adenocarcinoma; Nivolumab; Vitiligo

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; LEVOTHYROXINE; NIVOLUMAB; THYROGLOBULIN ANTIBODY; THYROTROPIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BACK; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CASE REPORT; CHRONIC DISEASE; COMPUTER ASSISTED TOMOGRAPHY; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; LIMB; LUNG ADENOCARCINOMA; LYMPHADENOPATHY; MALE; MEDICAL HISTORY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; SMOKING; THORAX; THORAX RADIOGRAPHY; THYROID FUNCTION TEST; THYROIDITIS; THYROTROPIN BLOOD LEVEL; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE; TRUNK; TUMOR BIOPSY; VITILIGO; ADENOCARCINOMA; ADVERSE DRUG REACTION; CANCER STAGING; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; PATHOLOGY; PROCEDURES; REMISSION; SKIN;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; REMISSION INDUCTION; SKIN; VITILIGO;

EID: 85018953581     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.04.019     Document Type: Article

References (17)

1. [1] Ezzedine, K., Lim, H.W., Suzuki, T., et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigm. Cell Melanoma Res. 25 (2012), E1–E13.
2. [2] Lerner, A.B., Nordlund, J.J., Should vitiligo be induced in patients after resection of primary melanoma. Arch. Dermatol., 113, 1977, 421.
3. [3] Lerner, A.B., Nordlund, J.J., Vitiligo. What is it? Is it important?. JAMA 239 (1978), 1183–1187.
4. [4] Albert, D.M., Sober, A.J., Fitzpatrick, T.B., Iritis in patients with cutaneous melanoma and vitiligo. Arch. Ophthalmol. 96 (1978), 2081–2084.
5. [5] Quaglino, P., Marenco, F., Osella-Abate, S., et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann. Oncol. 21 (2010), 409–414.
6. [6] Boasberg, P.D., Hoon, D.S., Piro, L.D., et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J. Invest. Dermatol. 126 (2006), 2658–2663.
7. [7] Rosenberg, S.A., White, D.E., Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphas. Tumor Immunol. 19 (1996), 81–84.
8. [8] Sibaud, V., Robert, C., Pigmentary disorders induced by anticancer agents. Part II: targeted therapies. Ann. Dermatol. Venereol. 140 (2013), 266–273.
9. [9] Tarhini, A., Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo), 2013, 2013, 857519.
10. [10] van Geel, N.A., Mollet, I.G., De Schepper, S., et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigm. Cell Melanoma Res. 23 (2010), 375–384.
11. [11] van den Boorn, J.G., Konijnenberg, D., Dellemijn, T.A., et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. 129 (2009), 2220–2232.
12. [12] Mandelcorn-Monson, R.L., Shear, N.H., Yau, E., et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J. Invest. Dermatol. 121 (2003), 550–556.
13. [13] Yee, C., Thompson, J.A., Roche, P., et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192 (2000), 1637–1644.
14. [14] Yin, E.S., Totonchy, M.B., Leventhal, J.S., Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: a novel finding. JAAD Case Rep. 3 (2017), 90–92.
15. [15] Wu, J., Hong, D., Zhang, X., et al. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci. Rep., 7, 2017, 44173.
16. [16] Teulings, H.E., Limpens, J., Jansen, S.N., et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33 (2015), 773–781.
17. [17] Tewalt, E.F., Cohen, J.N., Rouhani, S.J., et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8T cells. Blood 120 (2012), 4772–4782.